Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

234 Press Releases
DateTitleCompany
17 Apr 15 New international survey of lung cancer oncologists highlights underutilization of personalized treatments Boehringer Ingelheim,
Published by
Business Wire
30 Mar 15 Type 2 diabetes: CHMP recommends empagliflozin/metformin hydrochloride for approval in the European Union Boehringer Ingelheim and Lilly
30 Mar 15 Type 2 Diabetes: CHMP Recommends Empagliflozin/Metformin Hydrochloride for Approval in the European Union Boehringer Ingelheim,
Published by
Business Wire
23 Mar 15 Boehringer Ingelheim’s investigational biologic cleared skin better than ustekinumab in head-to-head Phase II psoriasis study Boehringer Ingelheim,
Published by
PharmiWeb.com
20 Mar 15 Boehringer Ingelheim’s investigational biologic cleared skin better than ustekinumab in head-to-head Phase II psoriasis study Boehringer Ingelheim,
Published by
Business Wire
16 Mar 15 Many Atrial Fibrillation patients at high risk of stroke fail to receive guideline-recommended oral anticoagulant treatment Boehringer Ingelheim,
Published by
Business Wire
13 Mar 15 EFSD and Boehringer Ingelheim: celebrating joint research and support Academic Diabetes Research in Europe Boehringer Ingelheim
12 Mar 15 EFSD and Boehringer Ingelheim: celebrating joint research and support Academic Diabetes Research in Europe Boehringer Ingelheim, EFSD,
Published by
PharmiWeb.com
03 Mar 15 Boehringer Ingelheim submits applications for approval of idarucizumab* specific reversal agent to dabigatran etexilate (Pradaxa®) to EMA FDA and Health Canada Boehringer Ingelheim,
Published by
Business Wire
27 Jan 15 New large-scale study to investigate effect of tiotropium + olodaterol Respimat® on exacerbations in COPD Boehringer Ingelheim,
Published by
Business Wire
15 Jan 15 35 Partners from Industry and Academia to Join European Research Initiative for the Prevention of Alzheimer’s Dementia Boehringer Ingelheim,
Published by
Business Wire
12 Jan 15 The Lancet Oncology publishes Phase III data showing Giotrif® (afatinib*) significantly extended overall survival of lung cancer patients with the most common EGFR mutation over chemotherapy Boehringer Ingelheim,
Published by
Business Wire
17 Dec 14 Dabigatran etexilate (Pradaxa®) green-lighted by NICE for treating and preventing the recurrence of deep vein thrombosis and pulmonary embolism. Boehringer Ingelheim Limited,
Published by
Business Wire
19 Nov 14 New data show dabigatran-specific antidote idarucizumab* restores blood clotting mechanism in humans Boehringer Ingelheim,
Published by
Business Wire
16 Oct 14 Boehringer Ingelheim’s OFEV™ (nintedanib*) approved by the FDA for the treatment of idiopathic pulmonary fibrosis Boehringer Ingelheim,
Published by
Business Wire
13 Oct 14 Boehringer Ingelheim Buoyed as Two Medicines Receive Scottish Medicines Consortium (SMC) Green Light for Use within the NHS Boehringer Ingelheim,
Published by
Business Wire
01 Oct 14 Asthma: Spiriva® (tiotropium) Respimat® becomes the only LAMA licensed in asthma care Boehringer Ingelheim
27 Sep 14 Afatinib? demonstrates superior progression-free survival compared to erlotinib in head-to-head Phase III trial in patients with advanced squamous cell carcinoma of the lung after failure of platinum based chemotherapy Boehringer Ingelheim,
Published by
Business Wire
19 Sep 14 Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy Boehringer Ingelheim,
Published by
Business Wire
16 Sep 14 Boehringer Ingelheim Named to Working Mother’s “100 Best Companies for Working Mothers” List Boehringer Ingelheim,
Published by
Business Wire
16 Sep 14 Type 2 Diabetes: Investigational empagliflozin/linagliptin combination tablet shows sustained reduction in blood glucose in Phase III study Boehringer Ingelheim,
Published by
Business Wire
09 Sep 14 TONADO™ study shows further lung function and quality of life benefits with tiotropium + olodaterol Respimat® fixed dose combination in COPD Boehringer Ingelheim
09 Sep 14 Diabetes: Boehringer Ingelheim and Eli Lilly and Company announce data on portfolio to be presented at the 50th EASD Annual Meeting Boehringer Ingelheim, Eli Lilly,
Published by
PharmiWeb.com
25 Aug 14 New Pradaxa® data to be presented at the ESC Congress 2014 Boehringer Ingelheim,
Published by
Business Wire
15 Jul 14 Pradaxa® (dabigatran etexilate) now available in the UK for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrence Boehringer Ingelheim
16 Jun 14 New survey in five European countries reveals urgent need to improve education about Acute Myeloid Leukaemia Boehringer Ingelheim,
Published by
Business Wire
15 Jun 14 Type 2 Diabetes: Physicians worldwide agree early conversations are crucial in the management of condition Boehringer Ingelheim,
Published by
Business Wire
06 Jun 14 ADDING MULTIMEDIA: Pradaxa® gains EU approval for treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism Boehringer Ingelheim,
Published by
Business Wire
06 Jun 14 Pradaxa® gains EU approval for treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism Boehringer Ingelheim,
Published by
Business Wire
05 Jun 14 European Medicines Agency (EMA) accepts accelerated marketing authorisation application for nintedanib in IPF Boehringer Ingelheim
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.